These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 16973418)
21. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517 [TBL] [Abstract][Full Text] [Related]
22. Therapeutical effects of PPAR agonists assessed by biomarker modulation. Chinetti-Gbaguidi G; Fruchart JC; Staels B Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909 [TBL] [Abstract][Full Text] [Related]
23. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Libby P; Plutzky J Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056 [TBL] [Abstract][Full Text] [Related]
24. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists. Benz V; Kintscher U; Foryst-Ludwig A Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460 [TBL] [Abstract][Full Text] [Related]
25. A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism. Xu C; Wang LL; Liu HY; Ruan CM; Zhou XB; Cao YL; Li S Biotechnol Lett; 2006 Jun; 28(12):863-8. PubMed ID: 16786270 [TBL] [Abstract][Full Text] [Related]
26. PPAR agonists and the metabolic syndrome. Staels B Therapie; 2007; 62(4):319-26. PubMed ID: 17983557 [TBL] [Abstract][Full Text] [Related]
28. Tesaglitazar: a promising approach in type 2 diabetes. Cox SL Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256 [TBL] [Abstract][Full Text] [Related]
29. Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. Devasthale PV; Chen S; Jeon Y; Qu F; Ryono DE; Wang W; Zhang H; Cheng L; Farrelly D; Golla R; Grover G; Ma Z; Moore L; Seethala R; Sun W; Doweyko AM; Chandrasena G; Sleph P; Hariharan N; Cheng PT Bioorg Med Chem Lett; 2007 Apr; 17(8):2312-6. PubMed ID: 17292606 [TBL] [Abstract][Full Text] [Related]
30. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors. Yumuk VD Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746 [TBL] [Abstract][Full Text] [Related]
31. [Nuclear receptors PPAR as a drug target in metabolic disorders]. Stolarczyk M; Gutman W; Derlacz RA Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422 [TBL] [Abstract][Full Text] [Related]
32. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874 [TBL] [Abstract][Full Text] [Related]
34. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150 [TBL] [Abstract][Full Text] [Related]
35. Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. Liu W; Liu K; Wood HB; McCann ME; Doebber TW; Chang CH; Akiyama TE; Einstein M; Berger JP; Meinke PT J Med Chem; 2009 Jul; 52(14):4443-53. PubMed ID: 19530681 [TBL] [Abstract][Full Text] [Related]